Navigation Links
Oculus Innovative Sciences Microcyn Technology Presented in Poster,at European Wound Management Association Conference

PETALUMA, Calif.--(BUSINESS WIRE)--May 14, 2007 - Oculus Innovative Sciences, Inc. (NASDAQ:OCLS) today reported that its Microcyn Technology was the subject of a poster presentation at the European Wound Management Association (EWMA) conference that was held in Glasgow, Scotland this past week.

The poster, entitled Clinical Results About an Antimicrobial Solution in the Treatment of Infected Chronic Wounds, utilized Cutting & Harding infection criteria to evaluate the performance of the Microcyn Technology plus antibiotics versus a control group of povidone iodine plus antibiotics. Forty patients with infected wounds were randomized into the two groups; 20 each in the Microcyn and povidone iodine groups. Analyzed data included: pain (VAS), improvement/resolution of the clinical signs of infection, bad odour reduction, white blood cells count and duration of hospitalization.

The study, led by investigators E. Ricci, S. Astolfi and R. Cassino of the operative unit of vulnology at the San Luca Clinic in Turin, Italy, concluded that the Microcyn Technology showed better results than did the povidone iodine group in reduced number of days of hospitalization, reduction of clinical signs of infection and pain reduction.

Dr. Andres Gutierrez, director of medical affairs for Oculus Innovative Sciences, said, "This poster, along with the dozen other international clinical studies conducted to date, further supports the use of Microcyn Technology in the treatment of infected wounds. Encouraged by these data, we have initiated several study sites for the FDA Phase II trial in the treatment of mildly infected diabetic foot ulcers in the United States."

Microcyn Technology, with three 510k FDA clearances in the United States for cleaning, moistening, lubricating and debriding wounds, is not approved in the U.S. for treatment of infection.

About Oculus

Oculus Innovative Sciences is a bio pharmaceutical company that develops, manufactures and markets a family of Microcyn(R) Technology-based products intended to help prevent and treat infections in chronic and acute wounds. Oculus' platform technology, called Microcyn, is a non-irritating oxychlorine compound designed to treat a wide range of pathogens, including antibiotic-resistant strains of bacteria, viruses, fungi and spores.

Oculus' principal operations are in Petaluma, California, and it conducts operations in Europe and Latin America through its wholly-owned subsidiaries, Oculus Innovative Sciences Netherlands B.V. and Oculus Technologies of Mexico, S.A. de C.V. Our website is www.oculusis.com.

Forward-Looking Statements

Except for historical information herein, the matters set forth in this press release are forward-looking within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are identified by the use of words such as "intended," "reduce," "reduction," and "designed," among others. These forward-looking statements are based on Oculus Innovative Sciences, Inc.'s current expectations. Investors are cautioned that such forward-looking statements in this press release are subject to certain risks and uncertainties inherent in the Company's business including risks inherent in the development and commercialization of potential products, the risk that scientific data may not be sufficient to meet regulatory standards or receipt of required regulatory clearances or approvals, the Company's future capital needs, and its ability to obtain additional funding and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission including the quarterly report on Form 10-Q for the quarter ended December 31, 2006. Oculus Innovative Sciences disclaims any obligation to update these forward-looking statements.

Oculus and Microcyn are trademarks or regis tered trademarks of Oculus Innovative Sciences, Inc.

Contact

Oculus Innovative Sciences, Inc.
Director of Public and Investor Relations
Dan McFadden, 425-753-2105
dmcfadden@oculusis.com
or
The Ruth Group
Investors:
Sara Ephraim, 646-536-7002
sephraim@theruthgroup.com
or
Media:
Jason Rando / Janine McCargo, 646-536-7025 / 7033
jrando@theruthgroup.com
jmccargo@theruthgroup.com


'"/>




Related medicine technology :

1. Next Safety, Inc.s Innovative Drug Delivery System Will Replace Cigarettes and Significantly Advance Pulmonary Medication Delivery
2. Innovative Cancer Drug MabThera Again Shown To Improve Survival Rates In Patients With Lymphoma
3. DNA Therapeutics Reports a Novel Mechanism of Action and a Biomarker of its Lead Molecule Dbait That Open an Innovative Pathway-Targeting in Molecular Cancer Therapy
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. YM BioSciences Announces Preclinical Data Confirming Nimotuzumab Binds to the EGF Receptor and Potentiates Radiotherapy
6. Suven Life Sciences Presenting Pre-clinical data of their NCE’s SUVN-502 and SUVN-507at International Brain Research Organization (IBRO) 2007 World Congress of Neuroscience
7. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
8. Advanced Life Sciences to Host Conference Call to Discuss Data From Cethromycins First of Two Phase 3 Pneumonia Trials
9. Sangamo BioSciences Announces Presentation of Phase 1 ZFP Therapeutic Data at American Diabetes Association Meeting
10. Answerthink and LORENZ Life Sciences Group Announce Strategic Alliance for the SAP Life Science Industry
11. Geron Corp. Licensee TA Sciences Announces Landmark 7/07/07 Teleconference to Answer Questions About TA-65, Their Telomerase Activator With Proven Age Management Benefits
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... India , May 25, 2016 ... Review, H1 2016"market research report that provides an ... with comparative analysis at various stages, therapeutics assessment ... of administration (RoA) and molecule type, along with ... It also reviews key players involved in the ...
(Date:5/24/2016)... , May 24, 2016   ... demonstrating non-inferiority in overall bowel cleansing and superiority in ... c leansing of the ... ) , Norgine B.V. today announced new positive ... PEG and ascorbate bowel preparation) versus standard 2 litre PEG with ...
(Date:5/24/2016)... 2016 Celsion Corporation (NASDAQ: ... provided an update on its ongoing OVATION study, ... GEN-1, the Company,s DNA-based immunotherapy, with the standard ... with advanced ovarian cancer who will undergo neoadjuvant ... an IL-12 DNA plasmid vector formulated as a ...
Breaking Medicine Technology:
(Date:5/25/2016)... ... May 25, 2016 , ... America Walks , a ... M.S.L., M.S.P.A., of the University of Pittsburgh Graduate School of Public Health , ... Ms. Reichbaum and 24 other advocates from around the country to participate in a ...
(Date:5/25/2016)... ... May 25, 2016 , ... Laser Skin & Wellness Center is ... of time of female aging. The Julietâ„¢ procedure helps to reverse ... as leakage, laxity, itchiness and pain have reported real relief from these and other ...
(Date:5/25/2016)... ... May 25, 2016 , ... BeniComp Insurance Company, a leading ... their clients' employee participation for their wellness initiatives. BeniComp clients experience nearly ... health plan with outcome-based deductible incentives. As a result, BeniComp clients have been ...
(Date:5/25/2016)... ... ... Consumer access to organic foods and grower access to food processers is ... cereals and other plant-based foods, will introduce the first consumer product (a new breakfast ... Hesco/Dakota Organic Products. , The transitional designation means the cereal was made using at ...
(Date:5/25/2016)... ... May 25, 2016 , ... HealthPostures , a national ... leading engineers at the American Society of Safety Engineers Conference in Atlanta, Georgia. ... , Engineers, speakers and exhibitors from more than 40 countries are scheduled to ...
Breaking Medicine News(10 mins):